US 5173414A
· Lebkowski et al.
· 1992
[cited by applicant]
US 5658776A
· Flotte et al.
· 1997
[cited by applicant]
US 5786211A
· Johnson
· 1998
[cited by applicant]
US 5871982A
· Wilson et al.
· 1999
[cited by applicant]
US 6258595B1
· Gao et al.
· 2001
[cited by applicant]
US 6566118B1
· Atkinson et al.
· 2003
[cited by applicant]
US 8668927B2
· Reiser et al.
· 2014
[cited by applicant]
US 9434928B2
· Mendell et al.
· 2016
[cited by applicant]
US 20110081362A1
· Elledge
· 2011
[cited by examiner]
WO WO9513365A1
· 1995
[cited by applicant]
WO WO9513392A1
· 1995
[cited by applicant]
WO WO9617947A1
· 1996
[cited by applicant]
WO WO9706243A1
· 1997
[cited by applicant]
WO WO9708298A1
· 1997
[cited by applicant]
WO WO9709441A2
· 1997
[cited by applicant]
WO WO9721825A1
· 1997
[cited by applicant]
WO WO9809657A2
· 1998
[cited by applicant]
WO WO9911764A2
· 1999
[cited by applicant]
WO WO0183692A2
· 2001
[cited by applicant]
WO WO02053703A2
· 2002
[cited by applicant]
Dayton et al. The advent of AAV9 expands applications for brain and spinal cord gene delivery. Expert Opin Biol Ther. Jun. 2012 ;12(6): 757-766. (Year: 2012).
[cited by examiner]
Gholizadeh et al. Transduction of the central nervous system after intracerebroventricular injection of adeno-associated viral vectors in neonatal and juvenile mice. Hum Gene Ther Methods. Aug. 2013;24(4):205-13. Epub A…
[cited by examiner]
Aimiuwu et al. Modeling Gene Specific Therapy of DNM1 Epileptic Encephalopathy [abstract]. In: American Epilepsy Society meeting. Nov. 5, 2018. Abstract nr 1.116. (Year: 2018).
[cited by examiner]
Nidetz et al. Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery. Pharmacology & Therapeutics. 207 (2020) 107453. Epub Dec. 11, 2019. (Year: 2019).
[cited by examiner]
Colasante et al. dCas9-Based Scn1a Gene Activation Restores Inhibitory Interneuron Excitability and Attenuates Seizures in Dravet Syndrome Mice. Molecular Therapy. Jan. 8, 2020; (28) 1: 235-253. (Year: 2020).
[cited by examiner]
Nationwide Children's Hospital (n.d.). Vector Production Process. Research. https://www.nationwidechildrens.org/research/resources-infrastructure/innovation-and-technology/gmp-facility/vector-production-process (Year: 2…
[cited by examiner]
Iodice R, Ugga L, Aruta F, Iovino A, Ruggiero L. Facioscapulohumeral muscular dystrophy (FSHD) and multiple sclerosis: a case report. Acta Myol. Mar. 1, 2020;39(1):29-31. doi: 10.36185/2532-1900-005. PMID: 32607477; PMC…
[cited by examiner]
Aimiuwu et al., “RNAi-Based Gene Therapy Rescues Developmental and Epileptic Encephalopathy in a Genetic Mouse Model,” Mol. Ther., 28(7):1706-1716 (2020).
[cited by applicant]
Asinof et al., “Dynamin 1 isoform roles in a mouse model of severe childhood epileptic encephalopathy,” Neurobiol. Dis., 95:1-11 (2016).
[cited by applicant]
Asinof et al., “Independent Neuronal Origin of Seizures and Behavioral Comborbidities in an Animal Model of a Severe Childhood Genetic Epileptic Encephalopathy,” PLOS Genet., 11:e1005347 (2015).
[cited by applicant]
Boudreau et al., “Rapid Cloning and Validation of MicroRNA Shuttle Vectors: A Practical Guide,” Chapter 2 of Harper (Ed.), RNA Interference Techniques, Neuromethods, vol. 58, Springer Science Business Media, LLC (2011).
[cited by applicant]
Boumil et al., “A Missense Mutation in a Highly Conserved Alternate Exon of Dynamin-1 Causes Epilepsy in Fitful Mice,” PLoS Genet., 6:e1001046 (2010).
[cited by applicant]
Brereton et al., “Mutations in the PH Domain of DNM1 are associated with a nonepileptic phenotype characterized by developmental delay and neurobehavioral abnormalities,” Mol. Genet. Genomic Med., 6:294-300 (2018).
[cited by applicant]
Buono et al., “Reducing dynamin 2 (DNM2) rescues DNM2-related dominant centronuclear myopathy, ” PNAS, 115(43):11066-11071 (2018).
[cited by applicant]
Carter, “Adeno-associated virus vectors,” Current Opinions in Biotechnology, 3:533-539 (1992).
[cited by applicant]
Choudhury et al., “In Vivo Selection Yields AAV-B1 Capsid for Central Nervous System and Muscle Gene Therapy,” Mol. Ther., 24(7):1247-1257 (2016).
[cited by applicant]
Clark et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors are Biologically Active and Free of Detectable Helper and Wild-Type Viruses,” Hum. Gene Ther., 10(6):1031-1039 (1999).
[cited by applicant]
Clark et al., Gene Ther., “A Stable cell line carrying adenovirus-inducible rep and cap genes allows for infectivity titration of adeno-associated virus vectors,” 3:1124-1132 (1996).
[cited by applicant]
Clinical Trial #: NCT03650452—Aug. 28, 2018.
[cited by applicant]
Clinical Trial #: NCT04033159—Jul. 25, 2019.
[cited by applicant]
Clinical Trial #: NCT04442295—Jun. 22, 2020.
[cited by applicant]
Consortium, “De Novo Mutations in Synaptic Transmission Genes Including DNM1 Cause Epileptic Encephalopathies,” Am. J. Hum. Genet., 100:179 (2017).
[cited by applicant]
Davidson et al., “Current prospects for RNA interference-based therapies,” Nat. Rev. Genet., 12:329-40 (2011).
[cited by applicant]
De et al., “High Levels of Persistent Expression of α1-Antitrypsin Mediated by the Nonhuman Primate Serotype rh. 10 Adeno-associated Virus Despite Preexisting Immunity to Common Human Adeno-associated Viruses,” Mol. The…
[cited by applicant]
Dhindsa et al., “Epileptic encephalopathy-causing mutations in DNM1 impair synaptic vesicle endocytosis,” Neurol. Genet., 1:e4, 10 pages (2015).
[cited by applicant]
Diling et al., “Circular RNA NF1-419 enhances autophagy to ameliorate senile dementia by binding Dynamin-1 and Adaptor protein 2 B1 in AD-like mice,” Aging, 11(24):12002-12031 (2019).
[cited by applicant]
Gao et al., “Clades of Adeno-Associated Viruses Are Widely Disseminated in Human Tissues,” J. Virol., 78:6381-6388 (2004).
[cited by applicant]
Harper, “Progress and Challenges in RNA Interference Therapy for Huntington Disease,” Arch. Neurol., 66:933-938 (2009).
[cited by applicant]
Hermonat et al., “Use of adeno-associated virus as a mammalian DNA cloning vector: Transduction of neomycin resistance into mammalian tissue culture cells,” Proc. Natl. Acad. Sci. USA, 81:6466-6470 (1984).
[cited by applicant]
Kolnikova et al., “DNM1 encephalopathy—atypical phenotype with hypomyelination due to a novel de novo variant in the DNM1 gene,” Seizure, 56:31-33 (2018).
[cited by applicant]
Kunkel et al., “Analysis of deletions in DNA from patients with Becker and Duchenne muscular dystrophy,” Nature, 322(6074):73-77 (1986).
[cited by applicant]
Kunkel et al., “Upstream elements required for efficient transcription of a human U6 RNA gene resemble those of U1 and U2 genes even though a different polymerase is used,” Genes Dev. 2(2):196-204 (1988).
[cited by applicant]
Laughlin et al., “Cloning of infectious adeno-associated virus genomes in bacterial plasmids,” Gene, 23:65-73 (1983).
[cited by applicant]
Lebkowski et al., “Adeno-Associated Virus: a Vector System for Efficient Introduction and Integration of DNA into a Variety of Mammalian Cell Types,” Mol. Cell. Biol., 8(10:3988-3996 (1988).
[cited by applicant]
Li et al., “Clinical Assessments and EEG Analyses of Encephalopathies Associated with Dynamin-1 Mutation,” Front. Pharmacol., 10:1454, 10 pages (2019).
[cited by applicant]
Marsic et al., “Vector Design Tour de Force: Integrating Combinatorial and Rational Approaches to Derive Novel Adeno-associated Virus Variants,” Molecular Therapy 22(11):1900-1909 (2014).
[cited by applicant]
McCarty, “Self-complementary AAV Vectors; Advances and Applications,” Mol. Ther., 16(10):1648-1656 (2008).
[cited by applicant]
McLaughlin et al., “Adeno-Associated Virus General Transduction Vectors: Analysis of Proviral Structures,” J. Virol., 62:1963-1973 (1988).
[cited by applicant]
Morelli et al., “Allelle-specific RNA interference prevents neuropathy in Charcot-Marie-Tooth disease type 2D mouse models,” J Clin Invest. 129(12):5568-83 (2019).
[cited by applicant]
Mori et al., “Two novel adeno-associated viruses from cynomolgus monkey: pseudotyping characterization of capsid protein,” Virology 330(2):375-383 (2004).
[cited by applicant]
Muzyczka, “Use of Adeno-Associated Virus as a General Transduction Vector for Mammalian Cells,” Curr. Topics in Microbiol. and Immunol., 158:97-129 (1992).
[cited by applicant]
Paddison et al., “Stable suppression of gene expression by RNAi in mammalian cells,” Proc. Natl. Acad. Sci. USA, 99(3):1443-1448 (2002).
[cited by applicant]
Paul et al., “Increased Viral Titer Through Concentration of Viral Harvests from Retroviral Packaging Lines,” Hum. Gene Ther., 4:609-615 (1993).
[cited by applicant]
Paule et al., “Transcription by RNA polymerases I and III,” Nuc. Acids Res., 28(6):1283-1298 (2000).
[cited by applicant]
Perrin et al., “An experimental rabies vaccine produced with a new BHK-21 suspension cell culture process: use of serum-free medium and perfusion-reactor system,” Vaccine, 13:1244-1250 (1995).
[cited by applicant]
Samulski et al., “Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells,” Proc. Natl. Acad. S6. USA, 79:2077-2081 (1982).
[cited by applicant]
Samulski et al., “Helper-Free Stocks of Recombinant Adeno-Associated Viruses: Normal Integration Does Not Require Viral Gene Expression,” J. Virol., 63:3822-3828 (1989).
[cited by applicant]
Schenpp et al., “Highly Purified Recombinant Adeno-Associated Virus Vectors,” Methods Mol. Med., 69: 427-443 (2002).
[cited by applicant]
Senapathy et al., “Molecular Cloning of Adeno-associated Virus Variant Genomes and Generation of Infectious Virus by Recombination in Mammalian Cells,” J. Biol. Chem., 259(7):4661-4666 (1984).
[cited by applicant]
Tasfaout et al., “Antisense oligonucleotide-mediated Dnm2 knockdown prevents and reverts myotubular myopathy in mice,” Nature Communications, vol. 8—Article 15661 (2017).
[cited by applicant]
Tratschin et al., “A Human Parvovirus, Adeno-Associated Virus, as a Eucaryotic Vector: Transient Expression and Encapsidation of the Procaryotic Gene for Chloramphenicol Acetyltransferase,” Mol. Cell. Biol. 4(10):2072-2…
[cited by applicant]
Tratschin et al., “Adeno-Associated Virus Vector for High-Frequency Integration, Expression, and Rescue of Genes in Mammalian Cells,” Mol. Cell. Biol. 5: 3251-3260 (1985).
[cited by applicant]
Trochet et al., “Allele-specific silencing therapy for Dynamin 2-related dominant centronuclear myopathy,” EMBO Mol Med, 10(2):239-253 (2018).
[cited by applicant]
Von Spiczak et al., “DNM1 encephalopathy,” Neurology, 89:385-394 (2017).
[cited by applicant]
Wallace et al., “RNa Interference Inhibits DUX4-induced Muscle Toxicity In Vivo: Implications for a Targeted FSHD Therapy,” Mol. Ther. J. Am. Soc. Gene Ther., 20:1417-1423 (2012).
[cited by applicant]
Wallace et al., “RNAi Therapy for Dominant Muscular Dystrophies and other Myopathies,” Duan (Ed.), Section 7.3 of Chapter 7 in Muscle Gene Therapy, Springer Science Business Media, LLC, pp. 99-115 (2010).
[cited by applicant]
International Search Report and Written Opinion from International Application No. PCT/US22/24885 mailed Jan. 6, 2023.
[cited by applicant]
Nidetz et al., “Adeno-associated viral vector-mediated immune responses: Understanding barriers to gene delivery,” Pharmacology & Therapeutics, 207, 13 pages (2020).
[cited by applicant]